Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Guerrot, Dominique ^a,b,c   Dussaule, Jean Claude ^a,b,d   Mael Ainin, Mouna ^a,b   Xu Dubois, Yi Chun ^a,d   Rondeau, Eric ^a,b,d   Chatziantoniou, Christos ^a,b   Placier, Sandrine ^a,b  

^a HÔPITAL TENON   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ROUEN UNIVERSITY HOSPITAL   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LOSARTAN; MESSENGER RNA; TRANSCRIPTION FACTOR RUNX2; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; POSTN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FIBROSING ALVEOLITIS; GENE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; MALE; MOLECULAR PATHOLOGY; NEPHRITIS; NONHUMAN; PERIOSTIN GENE; PROTEIN DETERMINATION; PROTEINURIA; QUANTITATIVE ANALYSIS; RAT; RENOVASCULAR HYPERTENSION; REVERSAL REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR FIBROSIS; ALLOTRANSPLANTATION; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR DISEASE;

RATTUS;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CELL ADHESION MOLECULES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOSARTAN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, HOMOLOGOUS; VASCULAR DISEASES;

EID: 84857754003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031974     Document Type: Article

References (30)

1. Dussaule JC, Guerrot D, Huby AC, Chadjichristos C, Shweke N, et al. (2011) The role of cell plasticity in progression and reversal of renal fibrosis. Int J Exp Pathol 92: 151-157.
2. Chatziantoniou C, Dussaule JC, (2008) Is kidney injury a reversible process? Curr Opin Nephrol Hypertens 17: 76-81.
3. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, et al. (2004) Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res 94: 1203-1210.
4. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, et al. (1999) Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 100: 1901-1908.
5. Kang YS, Li Y, Dai C, Kiss LP, Wu C, et al. (2010) Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 78: 363-373.
6. Leask A, Abraham DJ, (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119: 4803-4810.
7. Guerrot D, Kerroch M, Placier S, Vandermeersch S, Trivin C, et al. (2011) Discoidin domain receptor 1 is a major mediator of inflammation and fibrosis in obstructive nephropathy. Am J Pathol 179: 83-91.
8. Placier S, Boffa JJ, Dussaule JC, Chatziantoniou C, (2006) Reversal of renal lesions following interruption of nitric oxide synthesis inhibition in transgenic mice. Nephrol Dial Transplant 21: 881-888.
9. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, et al. (2003) Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 14: 1132-1144.
10. Boffa JJ, Tharaux PL, Dussaule JC, Chatziantoniou C, (2001) Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37: 490-496.
11. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, et al. (1992) Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474.
12. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC, (2000) Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 36: 330-336.
13. Inserra F, Romano LA, de Cavanagh EM, Ercole L, Ferder LF, et al. (1996) Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. J Am Soc Nephrol 7: 676-680.
14. Adamczak M, Gross ML, Amann K, Ritz E, (2004) Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 15: 3063-3072.
15. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, et al. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361: 40-51.
16. Luvara G, Pueyo ME, Philippe M, Mandet C, Savoie F, et al. (1998) Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 18: 1408-1416.
17. Pechánová O, Dobesová Z, Cejka J, Kunes J, Zicha J, (2004) Vasoactive systems in L-NAME hypertension: the role of inducible nitric oxide synthase. J Hypertens 22: 167-173.
18. Campbell DJ, (2006) L-NAME hypertension: trying to fit the pieces together. J Hypertens 24: 33-36.
19. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, et al. (1999) Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 99: 2185-2191.
20. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, et al. (1999) Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 14: 1239-1249.
21. Li L, Fan D, Wang C, Wang JY, Cui XB, et al. (2011) Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-{beta}1 pathways in cardiac fibroblasts. Cardiovasc Res.
22. Li G, Oparil S, Sanders JM, Zhang L, Dai M, et al. (2006) Phosphatidylinositol-3-kinase signaling mediates vascular smooth muscle cell expression of periostin in vivo and in vitro. Atherosclerosis 188: 292-300.
23. Pohjolainen V, Rysä J, Näpänkangas J, Kööbi P, Eräranta A, et al. (2011) Left ventricular periostin gene expression is associated with fibrogenesis in experimental renal insufficiency. Nephrol Dial Transplant.
24. Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, et al. (2010) Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 120: 3520-3529.
25. Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, et al. (2007) Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin. Hypertension 49: 1409-1414.
26. Sorocos K, Kostoulias X, Cullen-McEwen L, Hart AH, Bertram JF, et al. (2011) Expression patterns and roles of periostin during kidney and ureter development. J Urol 186: 1537-1544.
27. Satirapoj B, Wang Y, Chamberlin MP, Dai T, LaPage J, et al. (2011) Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells. Nephrol Dial Transplant doi 10.1093/ndt/gfr670.28.
28. Sen K, Lindenmeyer MT, Gaspert A, Eichinger F, Neusser MA, et al. (2011) Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol 179: 1756-1767.
29. Wallace DP, Quante MT, Reif GA, Nivens E, Ahmed F, et al. (2008) Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor. Am J Physiol Renal Physiol 295: F1463-1471.
30. Helle F, Jouzel C, Chadjichristos C, Placier S, Flamant M, et al. (2009) Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. Am J Physiol Renal Physiol 297: F191-199.